Literature DB >> 22945337

Early recurrence after curative resection in oligonodular hepatocellular carcinoma.

Liang Huang1, Jing Li, Jianjun Yan, Jie Cao, Caifeng Liu, Xianghua Zhang, Mengchao Wu, Yiqun Yan.   

Abstract

BACKGROUND/AIMS: Often patients experience an unexpected early recurrence after hepatectomy for multinodular HCC. We conducted this retrospective study to observe the recurrence rate within 1 year after hepatectomy for oligonodular HCC (2 or 3 nodules) and investigate the risk factors for early recurrence.
METHODOLOGY: The study population consisted of 102 patients with 2 or 3 HCCs that received curative resection between January 2009 and December 2009. Clinicopathological data were collected and subjected to univariate and multivariate analysis.
RESULTS: Forty-three (42.2%) patients were diagnosed as with recurrence within 1 year after hepatectomy. According to univariate analysis, the risk factors for early recurrence were alpha-fetoprotein (AFP) >200 ng/mL, microvascular involvement and lack of complete tumor capsule; microvascular involvement was an independent predictive factor for early recurrence by multivariate analysis (HR, 4.02; 95% CI, 1.42-11.39, p=0.009).
CONCLUSIONS: There was a high rate of early recurrence for patients with oligonodular HCC (2 or 3 nodules) after hepatectomy. Microvascular involvement was an independent predictive factor for early recurrence, and adjuvant therapy, such as TACE, may be considered for those patients af

Entities:  

Mesh:

Year:  2013        PMID: 22945337     DOI: 10.5754/hge12580

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.

Authors:  Xin-Fei Xu; Hao Xing; Jun Han; Zhen-Li Li; Wan-Yee Lau; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Yong-Yi Zeng; Chao Li; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  JAMA Surg       Date:  2019-03-01       Impact factor: 14.766

Review 2.  Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.

Authors:  Jian-Hong Zhong; Qing-Lian Zhong; Le-Qun Li; Hang Li
Journal:  Tumour Biol       Date:  2014-08-14

3.  Vessels that encapsulate tumor clusters (VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma.

Authors:  Jia-Hong Wang; Xiao-Shan Li; Hong-Sheng Tang; Jin Wang; Shu-Zhong Cui; Run-Ya Fang; Jing-Jing Song; Yan-Lin Feng; Tian-Pei Guan; Qiang Ruan
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-01       Impact factor: 4.322

4.  RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma.

Authors:  Jian Zhang; Tian-Yi Jiang; Bei-Ge Jiang; Chun Yang; Ye-Xiong Tan; Ning Yang; Yu-Fei Pan; Zhi-Wen Ding; Guang-Zhen Yang; Meng-Chao Wu; Li-Wei Dong; Hong-Yang Wang
Journal:  Oncotarget       Date:  2015-02-20

5.  Beneficial effects of Cripto-1 for transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Xiao-Shan Li; Jia-Hong Wang; Xian-Zi Yang; Lei Ma; Yan-Xia Shi; Ye Song; Peng Jiang; Sha Gao; Ye Dong; Jin-Rong Lin; Chuan Jin
Journal:  Aging (Albany NY)       Date:  2019-05-27       Impact factor: 5.682

6.  Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Hua Yang; Jie Wang; Zehuan Li; Yi Yang; Liuxiao Yang; Yong Zhang; Yinghong Shi; Ya Cao; Jian Zhou; Zheng Wang; Qing Chen
Journal:  Front Oncol       Date:  2019-09-04       Impact factor: 6.244

7.  COCH predicts survival and adjuvant TACE response in patients with HCC.

Authors:  Chen Wang; Zhi-Wen Ding; Cheng-Gang Zheng; Siyuan Wang; Zhi-Heng Li; Zi-Mu Zhang; Jian Pan; Jian Wang; Chun Yang
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

8.  Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma.

Authors:  Jia-Hong Wang; Xiao-Ping Zhong; Yong-Fa Zhang; Xiao-Liang Wu; Shao-Hua Li; Pei-En Jian; Yi-Hong Ling; Ming Shi; Min-Shan Chen; Wei Wei; Rong-Ping Guo
Journal:  Cell Death Dis       Date:  2017-09-07       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.